pcn poster

Posters

Differences in Patient and Healthcare Professional Perspectives on the Key Impacts of Tardive Dyskinesia

Abstract: Background: Physical manifestations of tardive dyskinesia (TD) impact daily activities and present a substantial psychosocial burden.

08/20/2024

Dosing and Treatment Patterns of Deutetrabenazine When Initiated Using a 4-Week Patient Titration Kit: Interim Results of the START Study

Abstract: Background: Deutetrabenazine is a vesicular monoamine transporter type 2 inhibitor (VMAT2i) for treatment of adults with tardive dyskinesia (TD) and Huntington disease (HD)-rela...

08/20/2024

Drug-Drug Interactions With Vesicular Monoamine Transporter 2 Inhibitors: Population Estimate of Patients With Tardive Dyskinesia at Risk in Real-World Clinical Practice

Abstract: Background: Valbenazine and deutetrabenazine (vesicular monoamine transporter 2 inhibitors) are approved in the US for treatment of adults with tardive dyskinesia (TD). Valbenaz...

08/20/2024

Variables Associated with Remission in Patients Treated with Esketamine Nasal Spray or Quetiapine Extended Release: A Post Hoc Subgroup Analysis of the ESCAPE-TRD Study

Abstract: Objective: To examine baseline and disease characteristics of patients with treatment-resistant depression (TRD) who achieved remission at week 8 with quetiapine extended releas...

08/20/2024

When the treatment for psychogenic polydipsia backfires: the analysis of clozapine-induced neuroleptic malignant syndrome

Abstract: Our case involves a 64-year-old male with a past psychiatric history of schizoaffective disorder (bipolar type; on clozapine 400mg nightly) and who presented to the hospital for...

08/20/2024

Use of Stellate Ganglion Block for Treatment-Resistant Post-Traumatic Stress Disorder: A Case Report

Abstract: PTSD is defined as a group of symptoms which include intrusive flashbacks and re-experiences of a traumatic event, avoidance of any trauma related stimuli, negative changes in m...

08/20/2024

TMS use in neurological complications following Covid-19 vaccination.

Abstract: Abstract Background Neurological complications after covid-19 are well described. TMS plays a role in the treatment of this condition. However, the use of TMS in neurological co...

08/20/2024

Treating Major Depressive Disorder After Suboptimal Response to Antidepressant Treatment: Where Do Digital Mental Health Tools Fit in?

Abstract: Introduction: Less than half of patients receiving first-line antidepressant (ADT) treatment for major depressive disorder (MDD) achieve remission. When considering the next tre...

08/20/2024

Treatment Effect Sizes of Once-Daily Valbenazine for Tardive Dyskinesia and for Chorea Associated with Huntington’s Disease: Post-Hoc Analyses of Two Phase 3 Clinical Trials

Abstract: Once-daily valbenazine is approved for the treatment of tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD). Valbenazine effect sizes (Cohen’s d) for th...

08/20/2024

Treatment Patterns and Healthcare Resource Utilization Following Initiation of Aripiprazole Lauroxil Using a 1-Day Initiation Regimen

Abstract: Background: The long-acting injectable aripiprazole lauroxil (AL) initiated using a one-time injection of a NanoCrystal Dispersion formulation of AL (ALNCD) and a 30-mg dose of ...

08/20/2024

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products